What is the risk of acyclovir (antiviral medication) induced kidney injury and how can it be managed in patients with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Acyclovir-Induced Kidney Injury

Acyclovir causes reversible nephrotoxicity in up to 20% of patients receiving intravenous therapy, typically manifesting after 4 days of treatment through crystalluria and obstructive nephropathy, which can be prevented by slow infusion over at least 1 hour, maintaining adequate hydration, and adjusting doses for any degree of renal impairment. 1, 2

Mechanism and Timing of Injury

The nephrotoxicity occurs through crystal formation in renal tubules and collecting ducts, as acyclovir is predominantly excreted by the kidneys. 1, 3 The injury typically develops within 24-48 hours of administration, characterized by a rapid rise in serum creatinine. 4, 5 However, the most common presentation is after 4 days of intravenous therapy. 1, 2

Risk Factors for Nephrotoxicity

Patients at substantially increased risk include:

  • Those with pre-existing renal impairment, who require mandatory dose adjustment 1, 6
  • Patients receiving rapid IV bolus injections rather than slow infusions 3
  • Dehydrated patients or those with water restriction 4, 7, 3
  • Patients receiving high doses (particularly above standard dosing) 7
  • Those on concurrent nephrotoxic medications 6

Prevention Strategies

The following measures are essential to minimize nephrotoxicity risk:

  • Never administer acyclovir as a rapid IV bolus; always infuse slowly over at least 1 hour 2, 3
  • Maintain adequate hydration throughout therapy 1, 6
  • Calculate IV acyclovir doses based on ideal body weight 2
  • Monitor renal function at initiation and once or twice weekly during treatment 1
  • Perform regular renal function assessments within the first 48 hours of treatment for early detection 4

Dose Adjustments for Renal Impairment

Mandatory dose reductions based on creatinine clearance: 6

Creatinine Clearance Oral Dosing Adjustment IV Dosing Adjustment
>25 mL/min Standard dosing Standard dosing
10-25 mL/min Every 8 hours Every 12-24 hours
<10 mL/min Every 12 hours 2.5-5 mg/kg every 24 hours
Hemodialysis After dialysis 2.5-5 mg/kg every 24 hours, dosed after dialysis

The dose of acyclovir must be reduced in patients with pre-existing renal impairment because it is excreted via the kidneys. 1

Management of Established Nephrotoxicity

When acyclovir-induced nephrotoxicity is suspected:

  • Discontinue acyclovir immediately 4, 7
  • Increase hydration 7
  • Monitor renal function closely 7, 8

Renal function typically improves rapidly within 24 hours to 1 week after discontinuation and rehydration. 4, 7, 8 This nephropathy is reversible, with crystals being removed after cessation of treatment. 3

Clinical Presentation

Patients may present with:

  • Elevated BUN and serum creatinine (often the only findings) 8
  • Mild proteinuria 8
  • Normal urine output in many cases 8
  • Decreased GFR by >25% from baseline 1

Additional Serious Adverse Effects

Beyond nephrotoxicity, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) has been reported in immunocompromised patients, resulting in death in some cases, though this is rare. 1, 2 This complication has been specifically associated with high-dose valacyclovir (8 grams/day) but not at standard HSV treatment doses. 1

Special Considerations

In patients with chronic kidney disease requiring acyclovir: The risk must be balanced against treatment necessity, particularly for life-threatening conditions like HSV encephalitis where delayed treatment beyond 48 hours worsens outcomes. 1 In such cases, use reduced doses appropriate for creatinine clearance, avoid concurrent nephrotoxic drugs, and monitor renal function intensively. 1

Common pitfall: Failing to adjust doses in elderly patients, who have higher plasma concentrations due to age-related renal function decline. 6 Dosage reduction may be required in geriatric patients with underlying renal impairment. 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Acyclovir-Induced Nephrotoxicity and Side Effects

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Renal function after acyclovir intravenous injection.

The American journal of medicine, 1982

Research

Acute renal failure in a child associated with acyclovir.

Pediatric nephrology (Berlin, Germany), 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.